Despite significant improvements in survival for preterm infants, the rate of major neurodevelopmental impairment in survivors has not diminished [25]. The burden of neurodevelopmental disability due to preterm birth is still a significant challenge for neonatologists and public health. As a result, strategies designed to reduce adverse neurological outcomes have been a major perinatal research focus.
Experiments on piglets have demonstrated that rSO2 values under a certain threshold for prolonged periods are associated with cerebral damage [26]. Subsequently, rcSO2 may negatively impact the growing brains of preterm infants and their neurodevelopmental outcomes. Low rcSO2 was associated with lower developmental scores in very preterm infants at 2 years of age [27]. A report found that children surviving with sequelae had lower rcSO2 than children without sequelae. There was a direct correlation between the time spent with an rSO2 of ≤ 40% and adverse cerebral outcomes or early death.
The relationship between SpO2 and rcSO2 is not well established, SpO2 is not a reliable tool to fully inform about rcSO2 [28, 29]. Therefore, automated FiO2 control might be difficult to further improve the stability of rcSO2 [30].
Current studies have validated that RDW statistically correlates with National Institutes of Health stroke scale scores and grading in patients with stroke [31]. In another study, Söderholm et al. developed the claim that the incidence of stroke and cerebral infarction increases with the level of RDW in individuals. In addition, they found evidence of an association between high RDW levels and increased intimal-medial thickness (IMT) in the common carotid artery, which has also been recognized as a risk factor in ischemic stroke [32, 33].
Various underlying metabolic abnormalities, such as shortening of telomere length, oxidative stress, inflammation, poor nutritional status, dyslipidemia, hypertension, erythrocyte fragmentation, and alteration of erythropoietin function lead to both impaired erythropoiesis and abnormal RBC survival. An increased RDW mirrors a profound deregulation of erythrocyte homeostasis[34].
Whether RDW plays an active role in health and disease or simply behaves as a biomarker, it is increasingly clear that its clinical use should now be broadened beyond its conventional application for troubleshooting anemia.
A retrospective study of 596 critically ill pediatric patients by Ramby et al. found an association between RDW and prolonged pediatric intensive care unit (PICU) stay in those without sepsis, with 1.17 increased odds for each 1% increase in RDW [8]. Elevated RDW in preterm newborns and infants with IUGR was also significantly associated with early mortality [8]. A higher RDW value was significantly associated with worse clinical parameters, including PICU mortality. Thus, RDW could be a promising prognostic factor with the advantages of simple and easy measurement in critically ill pediatric patients [35].
The influence of some confounding factors, such as GA, BW, and nursing factors, were excluded by statistical analysis using R (http://www.R-project.org). Our study found a statistically significant positive correlation between the RDW and preterm rcSO2. An RDW of ≥ 17.84% over the first 14 days could significantly increase the risk of a preterm rcSO2 value of < 55%. This value may be applied in clinical practice and used during routine monitoring processes for preterm rcSO2 in NICU.
Accordingly, tools or biomarkers able to detect early infants at risk of cerebral hypoxia injury would be welcome, and our data suggest that RDW over the first 14 days could be one of these. In clinical settings, RDW is easily available to physicians as a parameter of the CBC and therefore does not incur additional costs, compared with other clinical biomarkers.